Chivu R D, Chivu Laura Ioana, Ion Daniela Adriana, Barbu Carmen, Fica Simona
Department of Pathophysiology II, "C. Davila" University of Medicine and Pharmacy, Bucharest.
Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):830-2.
Thiamazole is the most used antithyroid drug for thyrotoxicosis in Basedow-Graves' (BG) (autoimmune) disease and in toxic multinodular goitre (TMG) (non-autoimmune). This study aims to find whether allergic reactions to thiamazole occur more frequently during the treatment of BG than of TMG.
Retrospective study, of 128 patients newly diagnosed and treated for thyrotoxicosis in the first 6 months of 2006, in the Endocrinology Department of "Elias" Hospital, Bucharest. Cases were all patients treated with thiamazole who developed allergic reactions. Controls were all patients treated with thiamazole without allergic reactions. Risk factor was considered to be the presence of BG.
Cases group consisted of 6 patients. All 6 started treatment with thiamazole for BG, and developed allergic reactions after 2-4 weeks of treatment. When thiamazole was withdrawn, allergic symptoms ceased under antihistamines and steroids. In order to control the thyrotoxicosis, antihistamines and oral steroids was administered, together with thiamazole in slow increasing doses. After about 4 weeks under this combination, a tolerance to thiamazole seems to appear. Control group consisted of 122 patients who started thiamazole: 66 for BG and 56 for TMG (without allergic reactions).
Allergy to thiamazole was significantly associated with the autoimmune BG, and not with TMG (p = 0.03, OR = 11.04). None of the patients with TMG developed allergic reactions to the drug. Tolerance to this drug may occur.
甲巯咪唑是治疗巴塞多-格雷夫斯病(BG,自身免疫性疾病)和毒性多结节性甲状腺肿(TMG,非自身免疫性疾病)所致甲状腺毒症最常用的抗甲状腺药物。本研究旨在探讨甲巯咪唑过敏反应在BG治疗过程中是否比TMG治疗过程中更频繁发生。
回顾性研究,选取2006年上半年在布加勒斯特“埃利亚斯”医院内分泌科新诊断并接受甲状腺毒症治疗的128例患者。病例为所有接受甲巯咪唑治疗且发生过敏反应的患者。对照为所有接受甲巯咪唑治疗但未发生过敏反应的患者。危险因素被认为是BG的存在。
病例组由6例患者组成。所有6例均开始使用甲巯咪唑治疗BG,治疗2 - 4周后出现过敏反应。停用甲巯咪唑后,在使用抗组胺药和类固醇的情况下过敏症状消失。为控制甲状腺毒症,给予抗组胺药和口服类固醇,并与逐渐增加剂量的甲巯咪唑一起使用。在这种联合治疗约4周后,似乎出现了对甲巯咪唑的耐受性。对照组由122例开始使用甲巯咪唑的患者组成:66例为BG患者,56例为TMG患者(无过敏反应)。
对甲巯咪唑的过敏反应与自身免疫性BG显著相关,而与TMG无关(p = 0.03,OR = 11.04)。TMG患者均未出现该药物过敏反应。对该药物可能会产生耐受性。